Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic NK Cells in Relapsed AML
NCT00274846Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Mar 2005
- Primary completion
- Jun 2008
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic natural killer cells in acute myeloid leukemia (AML), sponsored by Masonic Cancer Center. Started Mar 2005; status: completed.
02
Drugs
allogeneic natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00274846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00274846.